Connor Clark & Lunn Investment Management Ltd. Buys 135,650 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 46.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 429,687 shares of the company’s stock after acquiring an additional 135,650 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Omnicell were worth $19,130,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its position in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after acquiring an additional 273 shares during the period. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after purchasing an additional 355 shares during the period. KBC Group NV raised its position in shares of Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after purchasing an additional 778 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Omnicell by 307.8% in the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock valued at $159,000 after purchasing an additional 2,699 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Omnicell stock opened at $32.28 on Friday. The firm’s 50 day simple moving average is $40.96 and its 200 day simple moving average is $43.38. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.51 billion, a PE ratio of 119.56, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the topic of several research reports. Bank of America lowered their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Benchmark reissued a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Finally, Wells Fargo & Company decreased their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Omnicell has a consensus rating of “Hold” and an average price target of $52.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.